Tirzepatide and semaglutide are getting the attention now, but orforglipron could be the next go-to drug for patients hoping to lose weight and improve their heart health—no injections required.

Abbott has warned healthcare providers about a new issue with the mobile power units of certain HeartMate 3 LVADs. 

"Lp(a) represents the most important potential potential paradigm shift in cardiovascular disease prevention that we'll experience over the next five to 10 years," Seth Baum, MD, explained in a new interview.

The interventional cardiologist was accused of prescribing a variety of drugs to his family and friends, but then picking them up himself for his own personal use. This settlement officially resolves those allegations. 

Competition was once fierce between interventional cardiologists and cardiac surgeons, but that has changed over the years. "It is absolutely a partnership," one veteran surgeon told Cardiovascular Business. 

Heartflow has officially gone public after selling more than 19 million shares of common stock during an upsized IPO. The California medtech company, known for its AI-powered CCTA evaluations, is now being traded on Nasdaq under the symbol HTFL.

Artificial intelligence's role in day-to-day patient care continues to grow. What should health systems and cardiology departments be thinking about as they shop for new technologies?

"We cannot accept a system where only those with means can benefit from life-changing drugs. We are a wealthy nation that spends trillions on healthcare. We must ensure that income and wealth do not determine access," explained JACC Editor-in-Chief Harlan M. Krumholz, MD.

Jaffar Khan, MD, explained his team's work using intravascular lithotripsy balloons in a cadaver heart to break up mitral annular calcification. 

New Hampshire-based Conformal Medical plans on using the funds to enroll more patients into an ongoing clinical trial.